H.C. Wainwright reiterates a Buy rating on shares of Compass Pathways (CMPS), telling investors in a research note that the Phase 3 COMP005 trial delivered a regulatory win for COMP360 and the Phase 3 COMP006 trial is positioned to build on that success. The ongoing COMP006 trial, which is exploring a fixed repeat dosing regimen, is on track for a 26-week data readout in 2H26 and is expected to provide insight into durability and re-dosing strategy with COMP360, the firm says.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Psychedelic: Exclusive talk with biotech company Compass Pathways
- Cathie Wood Marks Independence Day with Strategic Buys and a Major Sell-Off
- Cathie Wood’s ARK Investment buys 29K shares of Compass Pathways today
- Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
- Mike Davis to become CDER deputy director, Pink Sheet’s Gingery says